David Straus, John Radford, Joseph Connors, Won Seog Kim, Andrea Gallamini, Radhakrishnan Ramchandren, Jonathan Friedberg, Ranjana Advani, Martin Hutchings, Andrew Evens, Piotr Smolewski, Kerry Savage, Nancy Bartlett, Hyeon-Seok Eom, Jeremy Abramson, Cassie Dong, Frank Campana, Keenan Fenton, Markus Puhlmann, Stephen Ansell
CONTEXT: Overall survival (OS) benefit from upfront treatment with new over existing approaches has never been shown in first-line (1L) classical Hodgkin lymphoma (cHL). With newer therapies for relapsed/refractory disease, demonstrating improved OS with 1L therapy has been challenging. In ECHELON-1 (NCT01712490), 5-year follow-up analyses supported a long-term progression-free survival (PFS) benefit with 1L brentuximab vedotin, doxorubicin, vinblastine, and dacarbazine (A+AVD) vs doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) in patients with stage Ill/IV cHL...
October 2022: Clinical Lymphoma, Myeloma & Leukemia